cytarabine / Generic mfg. - LARVOL DELTA

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. (PubMed, Lancet) - P3 | "The addition of quizartinib to standard chemotherapy with or without allo-HCT, followed by continuation monotherapy for up to 3 years, resulted in improved overall survival in adults aged 18-75 years with FLT3-ITD-positive newly diagnosed AML. Based on the results from the QuANTUM-First trial, quizartinib provides a new, effective, and generally well tolerated treatment option for adult patients with FLT3-ITD-positive newly diagnosed AML."

Journal • P3 data • Acute Myelogenous Leukemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Transplantation • FLT3

Chromosomal Heterogeneity and Enrichment of Mitotic Regulatory Programs Reveal a Therapeutic Vulnerability in Cytarabine-Resistant FLT3-ITD AML. (PubMed, Curr Issues Mol Biol) - "Notably, combined TTK/Mps1 and FLT3 inhibition with luvixasertib and midostaurin synergistically suppressed cell viability in both resistant cell lines. These findings identify divergent FLT3 regulation, DCK downregulation, increased chromosomal heterogeneity, and enrichment of mitotic regulatory programs as key features associated with acquired cytarabine resistance. They also support the combined inhibition of TTK/Mps1 and FLT3 as a potential therapeutic strategy for cytarabine-resistant FLT3-ITD AML."

Heterogeneity • Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • DCK • FLT3

Sample-Specific Generalized Cross-Validation for Gene Network Analysis of Cytarabine Response in Cancer Cell Lines. (PubMed, Int J Mol Sci) - "The estimated networks also exhibited nonlinear structural changes across Cytarabine sensitivity levels, indicating that molecular interactions vary with drug response. These results demonstrate that doubleS-GCV provides an efficient and reliable model selection framework for sample-specific gene network analysis."

Journal • Preclinical • Oncology

Cold Atmospheric Plasma Reduces Migration and Viability of Oral Squamous Cell Carcinoma Cells and Increases E-Cadherin Expression. (PubMed, Curr Issues Mol Biol) - "Wound closure was assessed by wound-healing assay under proliferation-restricted conditions (50 μM Ara-C), while relative cellular metabolic activity was measured using WST-1... In these in vitro OSCC models, CAP exposure was associated with slower wound closure, lower WST-1 signal, increased E-cadherin, and reduced Cyclin A expression. These findings suggest further investigation of CAP as a potential modulator of OSCC cellular metabolic activity, adhesion-related markers, and cell-cycle-associated proteins."

Journal • Head and Neck Cancer • Oncology • Oral Cancer • Solid Tumor • Squamous Cell Carcinoma • CCNA2 • CDH1 • CDH2

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network (ASH 2024) - "In the context of ibrutinib- and high-dose cytarabine-containing induction immuno-chemotherapy and ibrutinib maintenance, the addition of ASCT failed to show FFS superiority, while increasing toxicity during maintenance/follow-up. According to the pre-defined decision strategy, ibrutinib+R-CHOP/R-DHAP induction followed by 2 years of ibrutinib maintenance should be the new standard of care in younger MCL patients, thus ending the era of ASCT for MCL patients."

Clinical • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • Transplantation

Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real-World Analysis From REALYSA, a LYSA Cohort. (PubMed, Hematol Oncol) - P=N/A | "Older patients were treated with bendamustine-rituximab (28%), R-CHOP (18%), and low-dose cytarabine (20%)...In the second-line setting (n = 72), most patients were POD24 (89%) and 56% received ibrutinib, yet outcomes remained poor (CR 24%, ORR 35%, median EFS and OS of 6.3 and 25.6 months, respectively). These findings underscore the need for improved strategies for older and high-risk patients. Retrospective landmark analyses suggest a potential association between RM and improved EFS but are limited by baseline differences between groups."

Journal • Real-world evidence • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology

The Infectious Toll of Venetoclax: A Disease-By-Disease Analysis Across Hematologic Malignancies (SOHO 2026) - " Infectious burden was highest in AML, where VEN combined with hypomethylating agents or low-dose cytarabine produced overall infection rates of 55% to 84%...In highrisk MDS, 77.6% of patients experienced grade 3/4 neutropenic events on VEN-azacitidine, including fatal neutropenic sepsis. CLL carried a comparatively lower incremental infection risk, although anti-CD20 combination partners introduced distinct concerns: HBV reactivation in 13% with obinutuzumab-containing regimens, COVID-19 fatality reaching 22.7% in severe cases, and CMV reactivation. MM represented the highest-risk setting; in BELLINI, grade 3–5 infections occurred in 42% of VEN-bortezomib-dexamethasone–treated patients vs 29% on placebo, contributing to the absence of overall survival benefit in the unselected population... Infectious toxicity in venetoclax-based therapy is disease-specific, partner-specific, and manageable with prophylaxis. Fluoroquinolone and mold-active antifungal prophylaxis reduce..."

Acute Myelogenous Leukemia • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Oncology

Marrow-Dominant Aggressive Progression of TP53-Altered CLL/SLL After Reactive Myelofibrosis: A Diagnostic and Therapeutic Challenge (SOHO 2026) - "Treatment was complicated only by transient grade 4 neutropenia, recovering within 3–5 days with filgrastim...Ruxolitinib was started with initial count normalization...The patient received 1 cycle of obinutuzumab plus DHAP... This case highlights marrow-dominant aggressive progression of high-risk CLL/SLL after reactive myelofibrosis, creating a clinically relevant diagnostic dilemma between blastoid CLL/SLL progression and Richter transformation. It underscores the need for integrated morphologic, immunophenotypic, molecular, and clinical assessment, especially where limited access to targeted therapy influences disease trajectory and treatment selection. CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone; CLL: chronic lymphocytic leukemia; COVID-19: coronavirus disease 2019; DHAP: dexamethasone, cytarabine, and cisplatin; IGHV: immunoglobulin heavy chain variable region; JAK2: Janus kinase 2; SLL: small lymphocytic lymphoma; TP53: tumor protein p53."

Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Myelofibrosis • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • Small Lymphocytic Lymphoma • IGH • JAK2 • TP53

A Window Study of Acalabrutinib & Rituximab, Followed By Chemotherapy & Autograft (ASCT) in Fit Patients with Treatment Naïve Mantle Cell Lymphoma (MCL): First Report of the Investigator-Initiated Australasian Leukaemia & Lymphoma Group NHL33 'Wamm' Trial (ASH 2023) - P2 | "RDHAOx chemotherapy (rituximab, dexamethasone, cytarabine, oxaliplatin) prior to ASCT provides a complete response (CR) rate of 77% and favourable toxicity compared to many induction regimens (Le Gouill Blood 2017). Furthermore, Obinutuzumab-DHAP yields undetectable minimum residual disease (MRD) in 85% of young MCL patients...Those with an objective response (CR or partial response-PR) underwent BEAM ASCT (carmustine, etoposide, cytarabine, melphalan) then AR maintenance (A; 1yr continuous & R; 3-monthly x 8 cycles)...An AR window yields a high ORR and compared to historical studies, improves post-chemo induction CR rates and MRD negativity. A telehealth model allowed rapid recruitment in a rare cancer."

Clinical • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Oncology • Pneumonia • Thrombocytopenia • TP53

Blastic Crisis of CML in a Patient With Underlying CLL (SOHO 2026) - "At that time, treatment for CLL with obinotuzumab (anti-CD20, Gazyva) plus venetoclax (iBCL2) was selected and initiated in December 2025. This report thus describes a very rare case of a possible double clone in a patient with CLL since 2021 who developed a blast crisis of CML, possibly originating from another clone, in 2026. 7+3: 7 days of cytarabine and an anthracycline for the first 3 days, BCRABL1: breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1, CD: cluster of differentiation, SUV-max: maximum standardized uptake value."

Clinical • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR • CD5

Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia. (PubMed, Blood) - P1/2 | "We have recently shown an association between an immune-infiltrated tumor microenvironment (TME) and resistance to cytarabine-based chemotherapy but responsiveness to flotetuzumab, a bispecific DART® antibody-based molecule to CD3ε and CD123...Stepwise dosing during week 1, pre-treatment dexamethasone, prompt use of tocilizumab and temporary dose reductions/interruptions successfully prevented severe IRR/CRS, resulting in acceptable tolerability...Flotetuzumab represents an innovative experimental approach associated with acceptable safety and encouraging evidence of activity in PIF/ER AML patients. Trial registration number: NCT02152956."

IO biomarker • Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD123

Cladribine and low-dose cytarabine as first salvage after hypomethylating agent and venetoclax in acute myeloid leukemia. (PubMed, Leuk Res) - "Serial molecular profiling identified heterogeneous patterns of clonal evolution across the treatment trajectory, including exploratory observations of high Clad/LDAC ORR in patients with emergent RAS-pathway clones at HMA/Ven failure. These findings highlight Clad/LDAC-based therapy as a salvage option with modest clinical activity following HMA/Ven."

Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • TP53

Clinical Outcomes of Reduced-Dose Whole-Brain Radiotherapy After Induction Chemotherapy for Primary Central Nervous System Lymphoma: A Retrospective Single-Institution Study (ASTRO 2026) - "Induction chemotherapy consisted of R-MPV (rituximab, methotrexate, procarbazine, and vincristine) up to seven cycles, followed by two cycles of high-dose cytarabine administered as consolidation after radiotherapy. Reduced-dose WBRT following induction chemotherapy provided durable disease control and favorable survival outcomes in a real-world PCNSL cohort. These findings support rdWBRT as an effective consolidative strategy. Further investigation of neurocognitive outcomes is warranted."

Clinical data • Retrospective data • B Cell Lymphoma • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Response-Directed Radiotherapy after Methotrexate-Based Systemic Therapy for Patients with Primary CNS Lymphoma (ASTRO 2026) - "The most common ST regimen was HD-MTX, Procarbazine, and Vincristine (MPV) +/- Rituximab (R) in 32/52 (62%) of pts, while 13/52 (25%) received HD-MTX +/- R, and 7/52 (13%) received other HD-MTX-based regimens. 16/52 pts (31%) received consolidative cytarabine... In pts with PCNSL treated with HD-MTX-based ST, an RT approach incorporating a boost to residual disease is associated with improved PFS. Further investigation into optimal consolidative strategies in pts with a PR following HD-MTX-based induction is warranted."

Clinical • CNS Lymphoma • Eye Cancer • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Primary Vitreoretinal Lymphoma • Secondary Central Nervous System Lymphoma

CR109124: A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies (clinicaltrials.gov) - P1 | N=196 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Mar 2027 ➔ Jun 2027

Trial completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • KMT2A • NPM1 • NUP214 • NUP98

MATRix Therapy in Primary CNS Lymphoma: A Case of Drug Induced Liver Injury (DILI) and a Review of the FDA Adverse Event Reporting System (FAERs) (ACG 2026) - "The MATRix regimen (methotrexate, cytarabine, thiotepa, rituximab) has emerged as an intensive induction strategy but carries substantial toxicity, predominantly myelosuppression. Utilizing FAERs database, RORs of these medications with the ADR of hepatitis were calculated as: methotrexate ROR 4.04 (95% CI 3.86-4.22), cytarabine ROR 1.92 (1.63-2.26), and combination ROR 2.02 (1.57-2.59). Severe hepatotoxicity during MATRix therapy may be more clinically significant than currently appreciated. This case, supported by FAERs disproportionality signals linking methotrexate and cytarabine to hepatitis both individually and in combination, challenges the perception of hepatotoxicity as a minor ADR."

Adverse events • Clinical • Review • CNS Lymphoma • Hematological Malignancies • Hepatology • Liver Failure • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • ROR1

A Rare Case of Myeloid Sarcoma of the Pancreas Mimicking Pancreatic Adenocarcinoma (ACG 2026) - "The patient received 4 cycles of cytarabine-based chemotherapy...RIGHT: High power view of peripheral smear from pancreatic mass showing aggregates of crushed atypical lymphoid cells. Morphologic and immunophenotypic features in conjunction with flow cytometry results and recent diagnosis of acute myeloid leukemia on bone marrow support the diagnosis of myeloid sarcoma."

Clinical • Acute Myelogenous Leukemia • Gastrointestinal Disorder • Gout • Hematological Malignancies • Hepatology • Inflammatory Arthritis • Leukemia • Oncology • Pancreatic Adenocarcinoma • Pancreatitis • Sarcoma • Solid Tumor • Thrombocytopenia • ANPEP • CD33 • CD34 • KIT

Extramedullary Pancreatic Myeloid Sarcoma: A Familiar Presentation of Relapsing Hematologic Malignancy (ACG 2026) - "Prompt treatment with high-dose cytarabine was initiated, however the patient ultimately progressed to a blast crisis roughly one-year later...C: Axial PET/CT view of pancreatic head mass. D: Coronal PET/CT view of pancreatic head mass and surrounding stuctures."

Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Hepatology • Leukemia • Myelodysplastic Syndrome • Oncology • Sarcoma • Solid Tumor • CD34 • CD68 • KIT • PTPRC • SPN

The Great Masquerader: Diffuse Large B-Cell Lymphoma Presenting as Malignant Biliary Obstruction (ACG 2026) - "Due to severe hyperbilirubinemia precluding standard anthracycline-based therapy, treatment was initiated with rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAOx) for cytoreduction. Figure: Figure 2. Computed Tomography four months after starting chemotherapy demonstrating (A) marked decrease in porta hepatis mass (4.5 cm × 3.5 cm) and (B) left internal-external biliary drainage catheter in place with mild residual central intrahepatic biliary ductal dilatation."

B Cell Lymphoma • Biliary Cancer • Cholangiocarcinoma • Cholestasis • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hepatology • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Pancreatic Cancer • Solid Tumor

A Single-center Retrospective Study of MIAD ± R Chemotherapy in Newly Diagnosed Primary Central Nervous System Lymphoma: Safety Profiles and Clinical Outcomes. (PubMed, Clin Lymphoma Myeloma Leuk) - "The MIAD ± R regimen is a viable treatment option for newly diagnosed PCNSL with favorable efficacy and an acceptable safety profile. Further prospective trials are warranted to verify its value in the first-line standard of treatment in PCNSL."

Clinical data • Journal • Retrospective data • CNS Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Berubicin Substituted for Cytarabine in a MATRix-Based Regimen for Isolated Central Nervous System Lymphoma: A Five-Patient Case Series from the BER-PUM Study. (PubMed, Curr Oncol) - P1/2 | "Berubicin is a doxorubicin analog developed to cross the blood-brain barrier...Patients received up to four 21-day cycles of rituximab, high-dose methotrexate, berubicin, and thiotepa, with between-patient and intrapatient berubicin dose escalation...Recruitment ended prematurely because berubicin became unavailable. This case series demonstrates the feasibility of MBTRIX, although the small sample and incomplete dose escalation preclude definitive conclusions regarding safety and efficacy."

Journal • CNS Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • Transplantation

Adult-Onset Central Nervous System Erdheim-Chester Disease Successfully Treated With Cladribine and Cytarabine: Case Report and Literature Review. (PubMed, EJHaem) - "This case suggests that combination chemotherapy may represent an optimal therapeutic strategy for adult patients with CNS ECD. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission."

Journal • CNS Disorders • Rare Diseases

CALGB 51101: Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma (clinicaltrials.gov) - P2 | N=113 | Completed | Sponsor: Alliance for Clinical Trials in Oncology | Active, not recruiting ➔ Completed

Trial completion • B Cell Lymphoma • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Transplantation

Total Phenolic Content, Antioxidant and Cytotoxic Activity of Three Jacaranda Species (Bignoniaceae). (PubMed, Chem Biodivers) - "For antioxidant activity, the cold extraction of J. mimosifolia twigs yielded the best results, while the hot extraction provided the best results for J. caroba leaf extract. Regarding cytotoxic activity against THP-1 and PBMC cell lines, the chloroform and methanolic extracts from J. mimosifolia twigs exhibited the best selectivity indices (SI = 5.17 and SI = 5.50, respectively), results superior to those of the standard drug Cytarabine (SI = 4.4)."

Journal • Hematological Malignancies • Leukemia • Oncology

Intermediate Dose of Arac as Safe and Effective Savage Therapy for Multiple Myeloma Poor Mobilizers (IMS 2026) - "Granulocyte-colony stimulating factor (G-CSF) with or without cyclophosphamide (Cy) and on demand plerixafor is currently a standard regimen for HSCs mobilization in MM patients, but the HSC collection success rate is still less than 100% (Mina R et al, Haematologica , 2024). We can therefore conclude that, even if in our limited number of poor mobilizers, mobilization with intermediate dose of Ara-C+G-CSF and plerixafor was adequate in all patients and it could be considered an effective and safe savage mobilizing strategy."

Hematological Malignancies • Infectious Disease • Multiple Myeloma • CD34